LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 333 of 535
Next
>>
>
8301 to 8325 of 13356 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Normalized Growth Rate Inhibition Value
BT-20	Buparlisib	0.04	uM	LJP5	3	H06	72	hr	1097	3605	3925	0.9184	0.9095
BT-20	Buparlisib	0.12	uM	LJP5	1	H05	72	hr	1097	2929	3735	0.7842	0.7429
BT-20	Buparlisib	0.12	uM	LJP5	2	H05	72	hr	1097	2903	3877	0.7486	0.7061
BT-20	Buparlisib	0.12	uM	LJP5	3	H05	72	hr	1097	3223	3925	0.8211	0.7967
BT-20	Buparlisib	0.37	uM	LJP5	1	H04	72	hr	1097	1879	3735	0.5031	0.3558
BT-20	Buparlisib	0.37	uM	LJP5	2	H04	72	hr	1097	1873	3877	0.4830	0.3412
BT-20	Buparlisib	0.37	uM	LJP5	3	H04	72	hr	1097	2100	3925	0.5350	0.4233
BT-20	Buparlisib	1.11	uM	LJP5	1	H03	72	hr	1097	1219	3735	0.3264	0.0613
BT-20	Buparlisib	1.11	uM	LJP5	2	H03	72	hr	1097	1098	3877	0.2832	0.0004
BT-20	Buparlisib	1.11	uM	LJP5	3	H03	72	hr	1097	1125	3925	0.2866	0.0137
BT-20	Buparlisib	3.33	uM	LJP5	1	H02	72	hr	1097	761	3735	0.2037	-0.1870
BT-20	Buparlisib	3.33	uM	LJP5	2	H02	72	hr	1097	717	3877	0.1849	-0.2083
BT-20	Buparlisib	3.33	uM	LJP5	3	H02	72	hr	1097	718	3925	0.1829	-0.2060
BT-20	Buparlisib	10	uM	LJP5	1	H01	72	hr	1097	627	3735	0.1679	-0.2714
BT-20	Buparlisib	10	uM	LJP5	2	H01	72	hr	1097	656	3877	0.1692	-0.2461
BT-20	Buparlisib	10	uM	LJP5	3	H01	72	hr	1097	581	3925	0.1480	-0.2923
BT-20	XL147	0.04	uM	LJP5	1	G12	72	hr	1097	4110	3735	1.1003	1.1112
BT-20	XL147	0.04	uM	LJP5	2	G12	72	hr	1097	4215	3877	1.0870	1.0937
BT-20	XL147	0.04	uM	LJP5	3	G12	72	hr	1097	4581	3925	1.1670	1.1752
BT-20	XL147	0.12	uM	LJP5	1	G11	72	hr	1097	4493	3735	1.2029	1.2204
BT-20	XL147	0.12	uM	LJP5	2	G11	72	hr	1097	4019	3877	1.0364	1.0397
BT-20	XL147	0.12	uM	LJP5	3	G11	72	hr	1097	4330	3925	1.1031	1.1096
BT-20	XL147	0.37	uM	LJP5	1	G10	72	hr	1097	4150	3735	1.1110	1.1228
BT-20	XL147	0.37	uM	LJP5	2	G10	72	hr	1097	4259	3877	1.0983	1.1057
BT-20	XL147	0.37	uM	LJP5	3	G10	72	hr	1097	4050	3925	1.0317	1.0343

|<
<<
Previous
Page 333 of 535
Next
>>
>
8301 to 8325 of 13356 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)